CARA THERAPEUTICS INC (CARA) Fundamental Analysis & Valuation

NASDAQ:CARA • US1407552082

Current stock price

5.32 USD
-0.23 (-4.14%)
At close:
5.43 USD
+0.11 (+2.07%)
After Hours:

This CARA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CARA Profitability Analysis

1.1 Basic Checks

  • In the past year CARA has reported negative net income.
  • In the past year CARA has reported a negative cash flow from operations.
  • CARA had negative earnings in 4 of the past 5 years.
  • CARA had a negative operating cash flow in each of the past 5 years.
CARA Yearly Net Income VS EBIT VS OCF VS FCFCARA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • With a Return On Assets value of -161.70%, CARA is not doing good in the industry: 83.42% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -161.7%
ROE N/A
ROIC N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CARA Yearly ROA, ROE, ROICCARA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • The Gross Margin of CARA (91.31%) is better than 93.47% of its industry peers.
  • CARA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARA Yearly Profit, Operating, Gross MarginsCARA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CARA Health Analysis

2.1 Basic Checks

  • CARA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CARA has been increased compared to 1 year ago.
  • The number of shares outstanding for CARA has been reduced compared to 5 years ago.
  • CARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CARA Yearly Shares OutstandingCARA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CARA Yearly Total Debt VS Total AssetsCARA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -26.56, we must say that CARA is in the distress zone and has some risk of bankruptcy.
  • CARA has a Altman-Z score of -26.56. This is amonst the worse of the industry: CARA underperforms 87.44% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.56
ROIC/WACCN/A
WACC9.58%
CARA Yearly LT Debt VS Equity VS FCFCARA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • CARA has a Current Ratio of 11.03. This indicates that CARA is financially healthy and has no problem in meeting its short term obligations.
  • CARA's Current ratio of 11.03 is amongst the best of the industry. CARA outperforms 86.43% of its industry peers.
  • A Quick Ratio of 10.81 indicates that CARA has no problem at all paying its short term obligations.
  • CARA has a better Quick ratio (10.81) than 85.93% of its industry peers.
Industry RankSector Rank
Current Ratio 11.03
Quick Ratio 10.81
CARA Yearly Current Assets VS Current LiabilitesCARA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CARA Growth Analysis

3.1 Past

  • The earnings per share for CARA have decreased strongly by -612.03% in the last year.
  • CARA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -66.02%.
  • The Revenue for CARA have been decreasing by -18.54% on average. This is quite bad
EPS 1Y (TTM)-612.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.05%
Revenue 1Y (TTM)-66.02%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%-51.56%

3.2 Future

  • Based on estimates for the next years, CARA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.45% on average per year.
  • CARA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 68.20% yearly.
EPS Next Y40%
EPS Next 2Y22.74%
EPS Next 3Y13%
EPS Next 5Y11.45%
Revenue Next Year-25%
Revenue Next 2Y-44.1%
Revenue Next 3Y58.04%
Revenue Next 5Y68.2%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CARA Yearly Revenue VS EstimatesCARA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
CARA Yearly EPS VS EstimatesCARA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. CARA Valuation Analysis

4.1 Price/Earnings Ratio

  • CARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CARA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARA Price Earnings VS Forward Price EarningsCARA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARA Per share dataCARA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • CARA's earnings are expected to grow with 13.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.74%
EPS Next 3Y13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CARA Dividend Analysis

5.1 Amount

  • CARA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CARA Fundamentals: All Metrics, Ratios and Statistics

CARA THERAPEUTICS INC

NASDAQ:CARA (4/15/2025, 8:00:02 PM)

After market: 5.43 +0.11 (+2.07%)

5.32

-0.23 (-4.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03
Earnings (Next)05-12
Inst OwnersN/A
Inst Owner Change-2.27%
Ins OwnersN/A
Ins Owner Change0%
Market Cap24.31M
Revenue(TTM)7.14M
Net Income(TTM)-70.87M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)22.19%
Min Revenue beat(2)-10.63%
Max Revenue beat(2)55%
Revenue beat(4)2
Avg Revenue beat(4)12.75%
Min Revenue beat(4)-17.21%
Max Revenue beat(4)55%
Revenue beat(8)4
Avg Revenue beat(8)-5.61%
Revenue beat(12)7
Avg Revenue beat(12)-4.97%
Revenue beat(16)8
Avg Revenue beat(16)-9.33%
PT rev (1m)0%
PT rev (3m)1100%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.55
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-13.56
FCFYN/A
OCF(TTM)-13.33
OCFYN/A
SpS1.56
BVpS-1.01
TBVpS-1.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -161.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.31%
FCFM N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 544.79%
Cap/Sales 14.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.03
Quick Ratio 10.81
Altman-Z -26.56
F-Score4
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)492.59%
Cap/Depr(5y)332.09%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-612.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.05%
EPS Next Y40%
EPS Next 2Y22.74%
EPS Next 3Y13%
EPS Next 5Y11.45%
Revenue 1Y (TTM)-66.02%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%-51.56%
Revenue Next Year-25%
Revenue Next 2Y-44.1%
Revenue Next 3Y58.04%
Revenue Next 5Y68.2%
EBIT growth 1Y56.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.9%
EBIT Next 3Y10.58%
EBIT Next 5Y5.61%
FCF growth 1Y34.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.84%
OCF growth 3YN/A
OCF growth 5YN/A

CARA THERAPEUTICS INC / CARA Fundamental Analysis FAQ

What is the fundamental rating for CARA stock?

ChartMill assigns a fundamental rating of 2 / 10 to CARA.


Can you provide the valuation status for CARA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CARA THERAPEUTICS INC (CARA). This can be considered as Overvalued.


How profitable is CARA THERAPEUTICS INC (CARA) stock?

CARA THERAPEUTICS INC (CARA) has a profitability rating of 1 / 10.


What is the financial health of CARA THERAPEUTICS INC (CARA) stock?

The financial health rating of CARA THERAPEUTICS INC (CARA) is 4 / 10.